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https://doi.org/10.1186/s40425-019-0649-2RESEARCH ARTICLE Open AccessCirculating tumor cells in advanced non-
small cell lung cancer patients are
associated with worse tumor response to
checkpoint inhibitors
Menno Tamminga1* , Sanne de Wit2, T. Jeroen N. Hiltermann1, Wim Timens3, Ed Schuuring3,
Leon W. M. M. Terstappen2 and Harry J. M. Groen1Abstract
Background: Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting
responses, but it is hard to predict which patients will profit from this treatment with the currently used marker,
programmed death ligand 1 (PD-L1). We hypothesized that circulating tumor cells (CTC) or tumor derived
extracellular vesicles (tdEV) are markers of treatment efficacy.
Methods: Patients with advanced NSCLC treated with checkpoint inhibitors were included. Blood was drawn at
baseline (T0) and at 4 weeks of treatment (T1) for analysis of CTC and tdEV using CellSearch®. Tumor response was
classified as partial or complete response based on the response evaluation criteria in solid tumors (RECISTv1.1)
measured 4–6 weeks after start of treatment. Durable response was defined as stable disease, partial or complete
response without disease progression at 6 months. Analyses were adjusted for covariables including PD-L1 expression.
Results: We included 104 patients (30 with a tumor response, 74 non-responders, 2 responses not evaluable due to
early death); 63 patients provided T1 samples. All patients were treated with PD-L1 inhibitors. The majority of patients
received second (85%) or third line (treatment with nivolumab monotherapy (89%).
CTC were present in 33/104 patients at T0 (32%) and 17/63 at T1 (27%), 9/63 patients had CTC (14%) at both time
points. The presence of CTC, both at T0 (OR = 0.28, p = 0.02,) and T1 (OR = 0.07, p < 0.01), was an independent
predictive factor for a lack of durable response and was associated with worse progression free and overall survival.
More tdEV were associated with shorter survival but not with response rate.
Conclusion: CTC occur in one third of advanced NSCLC patients and their presence is a predictive factor for a worse
durable response rate to checkpoint inhibitors. tdEV are associated with shorter survival but not with response.
Keywords: Circulating tumor cells (CTC), Non-small cell lung cancer (NSCLC), Immunotherapy, Checkpoint inhibitors,
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Lung cancer accounts for 13% of newly diagnosed can-
cer cases and is responsible for 19% of cancer related
deaths, translating to over a million deaths worldwide
annually [1, 2]. While checkpoint inhibitors have been
able to ensure long-lasting survival, this is only achieved
in approximately 20% of non-small cell lung cancer
(NSCLC) patients, whereas the remainder experiences
little or no benefit from this treatment [3, 4]. Some
patients have responses that are remarkable durable (> 6
months), but these are a subset of the patients who have
an initial response. Imaging does not identify these
patients, as even patients with stable disease can remain
stable for a prolonged time.
A biomarker that can accurately predict the response
to checkpoint inhibitors would therefore be of great clin-
ical benefit. At present the expression of programmed
death-ligand 1 (PD-L1) measured by immunohistochem-
istry (IHC) on tumor biopsies predicts tumor response
to a certain extent, but is not a robust predictor for an
individual patient [5].
Possible early markers of response to checkpoint in-
hibitors are circulating tumor cells (CTC) and tumor-
derived extracellular vesicles (tdEV) [6–9]. Both are
derived directly from the original tumor or metastatic
sites. CTC are epithelial tumor cells that have been
expunged into the bloodstream and can settle at a
secondary site to form metastases. Their presence has
been reported to be an independent prognostic marker
of relative short overall survival (OS) in several types
of cancer, including NSCLC [10–16]. It is possible that
the presence of CTC is a reflection of the tumor bur-
den or invasiveness causing them to be associated with
worse survival [10, 13, 17]. These characteristics allow
them to be used as a liquid biopsy in a less invasive
approach to obtain information on prognosis and
treatment management.
Similar to CTC, tdEV are derived from the tumor and
associated with worse survival in NSCLC and hormone
refractory prostate cancer [8, 18]. They are vesicles
expressing epithelial cell adhesion molecule (EpCAM)
and cytokeratin, but in contrast to CTC, do not have a
nucleus. Recently, de Wit et al. showed that tdEV can be
found in NSCLC and are associated with survival, using
tdEV≥18 per 7.5 mL blood as a cut off, based on healthy
controls [8].
Considering their value as a prognostic marker, we hy-
pothesized that the presence of CTC and higher tdEV
counts (≥18 tdEV /7.5 mL) are associated with a worse
early and durable tumor response rate to checkpoint
inhibitors in advanced NSCLC patients. For this purpose
we determined CTC and tdEV counts in a prospective
exploratory cohort of real life NSCLC patients treated
with checkpoint inhibitors.Methods
Patients
Patients with advanced NSCLC (stage IIIB and IV),
eligible for treatment with checkpoint inhibitors towards
PD-L1 or PD − 1 receptors were asked to participate in
this prospective exploratory cohort study. Patients
received routine checkpoint inhibitors intravenously.
Blood samples were drawn in the week before the start
of checkpoint inhibitor therapy (T0) and four to 6 weeks
after start of therapy (T1). All assessments were per-
formed by the treating physician and occurred without
knowledge of CTC and tdEV counts. Measured variables
included: age; gender; Eastern Cooperative Oncology
Group Performance Score (PS); smoking status; stage;
histology; treatment lines; tumor size; number of loca-
tions of metastases; PD-L1 expression detected with the
22C3 antibody; checkpoint inhibitor medication; tumor
response, time to progression and overall survival.
Additionally for adenocarcinoma patients tumor DNA
mutations were detected by next generation sequencing
with the Ion Torrent using an in-house panel (IonPGM-
v002) targeting hotspots in 24 genes with 82 amplicons
(targeted genes are: AKT, ALK, BRAF, EGFR, ERBB2,
ESR1, GNA11, GNAQ, GNAS, H3F3B, HRAS, IDH1,
JAK2, KIT, KRAS, MAP2K1, MET, NRAS, PDGFRA,
PIK3CA, POLE and ROS1), while FISH was used to de-
tect rearrangements of the ALK, ROS1 and RET genes
(Vysis Break Apart FISH probes). ALK rearrangements
were confirmed with immunohistochemistry.
For squamous cell carcinoma patients amplifications
of FGFR1 were detected with FISH [19, 20].
The study was approved by the Medical Ethical
Committee and informed consent was obtained from all
patients (METc nr. 2017/217).
Tumor response
Early tumor response was measured 4–6 weeks after
start of treatment using the revised Response Evaluation
Criteria In Solid Tumors (RECIST) v1.1 [21]. Patients
with stable disease (SD), progressive disease (PD) and
patients who had a non-evaluable response (NE) due to
early death were deemed as having no early tumor
response, while patients with a partial response (PR) or
complete response (CR) were seen as responders.
Durable response was defined as patients who had
either SD, PR or CR, with no progression measured by
RECIST v1.1 for at least 6 months [3, 4].
Enumeration of EpCAMhigh CTC and tdEV with CellSearch
Aliquots of 7.5 mL whole blood were enumerated for
CTC and tdEV with the CellSearch® Circulating Tumor
Cell Kit within 48 h after blood draw in a CellSave tube
(Menarini Silicon Biosystems, Huntingdon Valley PA,
USA). Blood from the CellSave tube was transferred to a
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800 g without using the brake, after which the sample
was placed in the CellSearch Autoprep for analysis. The
blood samples were immunomagnetically enriched for
cells and tdEVs expressing EpCAM and stained with
DAPI, CK-PE and CD45-APC. Image acquisition of the
CellSearch cartridges containing the enriched and
stained cell suspension was performed on the CellTracks
Analyzer II.Scoring of CTC and tdEV
CTC candidates in the images from the cartridges were
identified by the CellTracks Analyzer II and presented
to a trained operator for CTC classification per manu-
facturer instructions. CTC were defined as objects larger
than 4 μm in diameter, stained with DAPI and CK,
lacked CD45 staining and had morphological features
consistent with that of a cell [22]. All CellTracks images
from all cartridges were analyzed using the open source
imaging program ACCEPT [23–25]. In short, the
ACCEPT toolbox uses an advanced multi-scale segmen-
tation approach and extracts fluorescence intensity and
shape measurements for every event found. Based on
selection criteria selected by the user, the program can
present all events conforming to the criteria. The selec-
tion criteria used for tdEV were: CK mean intensity ≥60,
CK maximum intensity ≥90, CK standard deviation of
intensity ≥0.15, CK size < 150 μm2, CK perimeter
≥3.2 μm (≥5 pixels), CK roundness < 0.80 (where 0 is
perfectly round and 1 is a perfect line), CK perimeter to
area < 1.1, DNA mean intensity < 5, CD45 mean inten-
sity < 5. As the blood was centrifuged at 800 g and the
plasma discarded before processing on the CellSearch
system, the detected tdEV were relatively large vesicles
(> 1 μm) [26].Statistical analysis
Descriptive statistics were used for clinical characteris-
tics. Patients were separated in favorable and unfavor-
able groups based on the presence of CTC, and for 18
or more tdEV. The cut off value of 18 tdEV was used
previously by de Wit et al. and is based on the mean
tdEV count in 35 healthy donors (tdEV = 5.1), with two
standard deviations (6.7) [8].
The change in CTC and tdEV over time was calcu-
lated. This variable was subsequently dichotomized into
patients with 0 CTC at both time points or decreasing
CTC/tdEV counts (favorable group) and patients with
increasing CTC or tdEV counts (unfavorable).
Differences between patients in the favorable and
unfavorable group were compared by means of T-tests
and Mann-Whitney U tests for continuous variables and
Χ2 tests or Fishers exact test for categorical variables.The primary endpoints were differences in early tumor
and durable response rates between patients with and
without CTC and elevated or not elevated tdEV. If the
Χ2 or Fishers Exact test were significant, binary logistic
regression was used corrected for clinical parameters
and expressed as odds ratios (OR) for response (> 1 indi-
cates response benefit). In this multivariable model,
covariables were selected in a backward conditional
method, with p = 0.1 as a cutoff. In short, all previously
mentioned variables were included in the base model.
Covariables with a p > 0.1 were one by one removed
from the model, starting with the highest p value, until
all variables in the model had p < 0.01. The covariables
in the final model are reported.
Secondary endpoints, PFS and OS, were investigated
using Cox regression analyses. Covariables for these multi-
variable models were selected in the same way as for the
logistic regression analyses. Corrected Hazard ratios (> 1
indicates shorter survival) and p-values were provided for
CTC and tdEV independently. In all analyses, a p value of
0.05 or smaller was deemed significant. Outcomes from
the logistic regressions, indicating an association with re-
sponse rates were deemed predictive, while associations
from the Cox regression analyses, indicating an associ-
ation with survival, were seen as prognostic.Results
A total of 104 patients with advanced NSCLC who started
checkpoint inhibitors were included. T1 samples (obtained
between four and six weeks after start treatment) were ob-
tained in 63 of these cases. Of 41 patients no T1 sample
was obtained: 24 had progression or deceased before the
second sample could be taken, one patient refused a second
sample and 16 cases could not be obtained or processed.
Mutations were detected in 47/104 patients (45%), mostly
KRAS mutations (n = 33/104; 32%). These mutations were
not significantly associated with tumor response.
Early tumor responses (PR or CR measured at 4–6
weeks by RECISTv1.1) were observed in 30/104 pa-
tients (29%), with 4 CR, 26 PR, 24 SD and 48 PD.
Two patients had a non-evaluable response due to
early death (denoted as PD). Durable responses (SD,
PR or CR measured at 6 months) were observed in
40/104 patients (38%).
Patient characteristics are described in Table 1, with
an overview of CTC and tdEV counts in Table 2.
PD-L1 expression could not be determined in 23
patients (22%) as the tumor material was of insuffi-
cient quality or quantity for PD-L1 analysis. From
the remaining 81 patients, 44 (54%) had no PD-L1
expression (< 1%), 19 (23%) had PD-L1 expression
between 1 and 49% and 18 (22%) had PD-L1 expres-
sion ≥50% (Table 1).










at T0 (n = 71)
n (%) n (%) n (%)
Age
Median (range) 65 (29–83) 67 (41–83) 65 (29–80)
Gender
Male 58 (44) 17 (51) 41 (58)
Female 46 (56) 16 (49) 30 (42)
ECOG PS*
0 50 (48) 9 (27) 41 (58)
1 52 (50) 23 (70) 29 (41)
2 2 (2) 1 (3) 1 (1)
Smoking status
Smokers 94 (90) 28 (85) 66 (93)
Non smokers 3 (3) 2 (6) 1 (1)
Unknown 7 (7) 3 (9) 4 (6)
Stage
III 12 (11) 1 (3) 1 (16)
IV 92 (89) 32 (97) 60 (84)
Histology
Adenocarcinoma 76 (73) 24 (72) 52 (73)
Squamous cell carcinoma 27 (26) 8 (24) 19 (27)
Carcinosarcoma 1 (1) 1 (4) 0 (0)
Therapy line
1 4 (4) 3 (4) 1 (3)
2 87 (84) 59 (83) 28 (85)
≥3 13 (12) 9 (13) 4 (12)
Metastatic sites
0 15 (14) 2 (6) 13 (18)
1 37 (36) 13 (41) 24 (34)
2 35 (34) 12 (38) 23 (32)
3 10 (10) 4 (13) 6 (9)
> 3 6 (6) 1 (3) 5 (7)
Mutations a
None identified 46 (44) 18 (55) 39 (55)
KRAS 33 (32) 9 (27) 24 (34)
Other 14 (13) 6 (18) 8 (11)
PD-L1 b
< 1% 44 (43) 16 (49) 28 (39)
1–49% expression 19 (18) 7 (21) 12 (17)
≥50% expression 18 (17) 5 (15) 13 (18)
Not evaluable c 23 (22) 5 (15) 18 (25)
Therapy
Nivolumab 89 (85) 29 (85) 60 (83)
Table 1 Characteristics of advanced NSCLC patients treated









at T0 (n = 71)
n (%) n (%) n (%)
Pembrolizumab 8 (8) 2 (6) 6 (9)
Atezolizumab 5 (5) 1 (3) 4 (7)
Ipilimumab/Nivolumab 2 (2) 1 (3) 1 (1)
Response d
Complete Response 4 (4) 0 (0) 4 (6)
Partial Response 26 (25) 7 (21) 19 (27)
Stable Disease 24 (23) 5 (15) 19 (27)
Progressive Disease 50 (48) 21 (61) 29 (39)
Durable response e
> 6months 64 (62) 7 (21) 33 (46)
< 6 months 40 (38) 26 (79) 38 (54)
*Eastern Cooperative Oncology Group Performance Score, patients with CTC
had significantly more often PS ≥1 than patients without CTC (p = 0.02)
aMutations were identified by NGS, specifically the Ion Torrent using an in-
house panel (IonPGM-v002) (adenocarcinoma). DNA amplifications and
rearrangements were detected by means of FISH (adenocarcinoma and
squamous cell carcinoma)
bPD-L1 expression was measured by certified pathologists on at least 100
tumor cells with 22C3 antibodies
cPD-L1 could not be evaluated in 23 patients as biopsied material was of
insufficient quality or quantity
dRevised Response Evaluation Criteria In Solid Tumor v1.1, Non evaluable was
due to early death of the patient
eDurable response was defined as SD, PR or CR for at least 6 months. Those
who had a shorter tumor response duration had more often CTC (p = 0.01)
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cases, significantly higher than patients with lower
PD-L1 expression wo responded in 17/63 (27%) cases
(OR = 3.0, p = 0.06 for early tumor response and OR =
2.9, p = 0.05 for durable tumor response).Presence of CTC
CTC were present in 33/104 T0 samples (32%), of whom
most had 1 CTC (n = 11/104; 11%). Ten out of all 104
patients (10%) had more than 5 CTC detected. At T1,
17/63 patients (27%) had CTC; of these patients 8 (47%)
did not have CTC at T0. Six patients who did have CTC
at T0 had no CTC detected at T1. Patients with CTC at
both time points showed an increase in three cases, and
a decrease in five cases. One patient had 1 CTC per 7.5
mL blood at both time points.
Out of the four patients who had a complete re-
sponse, 3 had 0 CTC at both T0 and T1. Of the 10
patients with CTC > 5 at T0, two patients had a
tumor response (PR), with durable responses being
observed in three patients (the two aforementioned
patients and one patient with SD).
Table 2 Circulating tumor cells and tumor derived extracellular vesicles
Biomarker Descriptive Median (range)/number of patients (%)
CTC at T0
(n = 104)
Median (range) 0 (0–141)
Patients with CTC 33 (32)
Patients with CTC > 5 10 (10)
CTC at T1
(n = 63)
Median (range) 0 (0–85)
Patients with CTC 17 (27)
Patients with CTC > 5 2 (3)
Change in CTC
(between T0 and T1)
(n = 63)
Median (range) 0 (− 8 − + 39)
Pts with decrease 11 (16)
Pts with increase 11 (17)
Pts with no change 41 (65)
tdEV at T0
(n = 104)
Median (range) 6.5 (0–1753)
Pts with tdEV≥18 27 (26)
tdEV at T1
(n = 63)
Median (range) 5 (0–1975)
Pts with tdEV≥18 11 (17)
Change in tdEV
(between T0 and T1)
(n = 63)
Median (range) -1 (−46 − + 222)
Pts with decrease 33 (52)
Pts with increase 29 (46)
Pts with no change 1 (2)
Circulating tumor cell (CTC) and tumor derived extracellular vesicle (tdEV) count measured by CellSearch in 7.5 mL of blood aided by automated imaging. For
automated imaging the Accept program was used, an open source program introduced by Zeune et al. [20–22]
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Patients with CTC at T0 did not respond differently
from those without CTC, with 7/33 (21%) versus 23/
71(32%) responding respectively (p = 0.2, Fig. 1). Patients
with CTC at T1 less often had a tumor response (2/17,
12%) compared to those without CTC at T1 (19/46,
41%; p = 0.04), but this difference was not significant
after adjustment for other factors (PD-L1, PS, number of
organs with metastases and histological subtype) (OR =
0.22, p = 0.08).
Patients who had no CTC at either time point (n = 40)
or decreasing CTC counts (n = 11) had a tumor response
in 20/51 cases (39%) while patients with increased or
stable CTC counts at T1 only responded in 1/12 cases
((8%; p = 0.04). In the multivariable analysis this difference
in response was no longer significant (OR = 0.13, p = 0.08).
CTC and durable response
Patients with CTC at T0 had a durable response in 7/33
cases (21%), which was significantly lower compared to pa-
tients without CTC at T0, who responded in 33/71 patients
(46%; p = 0.03). This relation remained significant after ad-
justment for covariables (age, PS, histological subtype, PD-
L1, number of organs with metastases, OR = 0.28, p = 0.02).
The presence of CTC at T1 was also predictive for
lower durable response rates. Patients with CTC at T1
had a durable response in 1/12 cases (12%) compared
to 25/46 cases (54%) without CTC at T1 (p < 0.01),which remained significant in the multivariable analysis
(OR = 0.07, p < 0.01).
Patients with either no CTC at both time points or de-
creasing CTC, had a durable response in 25/51 cases
(51%) versus 1/12 cases (8%) with increased CTC (p <
0.01). This association remained significant after adjust-
ment for the selected factors (OR = 0.04, p = 0.01).
Association of CTC with PFS and OS
Presence of CTC, adjusted for PS and histological subtype,
was correlated with PFS and OS at T0 (HR = 1.6, p = 0.05;
HR = 2.2, p < 0.01 respectively, Fig. 2), T1 (HR = 3.2, p <
0.01; HR = 3.2, p < 0.01 respectively). An increase in CTC
also corresponded with shorter PFS and OS (increased
CTC HR= 3.4, p < 0.01; HR = 3.7, p < 0.01 respectively).
After adding tumor response as a dichotomous vari-
able to the multivariable model, CTC were no longer
significantly correlated to a worse PFS at T0 (HR = 1.5,
p = 0.13), but remained associated with a worse OS at
T0 (HR = 1.89, p = 0.02), and worse PFS and OS at T1
(PFS HR = 3.6, p < 0.01; OS HR = 2.2, p = 0.03) and
when CTC counts increased after therapy (PFS HR =
4.46, p < 0.01; OS HR = 2.4, p = 0.04).
Presence of tumor derived extracellular vesicles (tdEV)
At T0, tdEV were present in 94 patients (90%, median 7,
range 0–1752), and at T1 in 66 patients (94%, median 5,
range 0–1975). There were 26 patients (25%) at T0 who
Fig. 1 Percentage of advanced non-small cell lung cancer (NSCLC) patients with an early response (partial and complete response according to
the revised response evaluation criteria in solid tumors v1.1 [RECIST 1.1],) and durable response (stable disease, partial response and complete
response according to RECIST 1.1 without progression in 6 months) to checkpoint inhibitors with and without circulating tumor cells (CTC) at T0
(a) and by increased or stable (ΔCTC) CTC counts when measured at 4 to 6 weeks of therapy (b). Early response rates were not significantly
different (T0: OR = 0.67, p = 0.56; ΔCTC OR = 0.13, p = 0.08) but durable response rate was significantly lowered in patients with CTC (T0 OR = 0.28,
p = 0.02; ΔCTC OR = 0.04, p = 0.01)
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(52%) there was a decrease of tdEV while in 29 cases
(46%) there was an increase, with only one patient
having the same number of tdEV at both measurements
(tdEV = 4).
Tumor derived extracellular vesicles (tdEV) and early
tumor response
Patients with tdEV< 18 and tdEV≥18 did not respond
differently, with respectively 7/27 (26%) and 23/77Fig. 2 Progression-free survival (PFS, a) and overall survival (OS, b) of patie
checkpoint inhibitors, stratified for baseline circulating tumor cells (CTC). M
shorter than that of patients without CTC (PFS: 1.4 months versus 4.8 mont
rank p < 0.01)(30%) early responders at T0 (p = 0.70, Additional file 1:
Fig. S1), and 18/52 (35%) and 3/11 (27%) early re-
sponders at T1 (p = 0.64).
Tumor derived extracellular vesicles (tdEV) and durable
tumor response
No significant difference in durable response rate was
observed between patients with tdEV< 18 and patients
with tdEV≥18 at both time points. At T0, 8/27 patients
(30%) with tdEV< 18 and 31/77 patients (40%) withnts with advanced non-small cell lung cancer (NSCLC) treated with
edian PFS and OS of patients with baseline CTC was significantly
hs, log rank p < 0.01, OS: 4.5 months versus 12.1 months, log
Tamminga et al. Journal for ImmunoTherapy of Cancer           (2019) 7:173 Page 7 of 9tdEV≥18 had a durable response (p = 0.33). At T1, 24/52
patients (46%) with tdEV< 18 and 3/11 patients (27%)
with tdEV≥18 had a durable response (p = 0.25).Association of tdEV with PFS and OS
Patients with elevated tdEV were associated with a shorter
PFS (T0: HR = 1.8, p = 0.03; T1: HR = 2.5, p = 0.02; ΔtdEV:
HR = 1.02, p < 0.01) and shorter OS (T0:HR = 2.4, p < 0.01,
T1: HR = 2.8, p = 0.02; ΔtdEV HR= 1.01, p < 0.01) in a mul-
tivariable model corrected for PS, histology, number of or-
gans with metastases and PD-L1 (Additional file 2: Fig. S2).Discussion
The currently clinically used biomarker for checkpoint
inhibitors is PD-L1 expression, but it is not robust
enough to predict therapy response on a per patient
basis. Tumor mutational burden likely predicts response
as well, but is not (yet) routinely used [4, 27–29].
We investigated the role of CTC and tdEV in patients
with advanced NSCLC treated with checkpoint inhibi-
tors in a real life patient population and observed that
CTC were an independent predictive factor for durable
tumor response rates, even after adjusting for other
factors [21, 30, 31]. Durable response rates were twice as
high for patients without CTC at baseline compared to
patients with CTC (OR = 0.28) and even six times as
high for patients with decreased CTC counts after
therapy compared to increased CTC counts (response
OR = 0.04).
CTC were not associated with early tumor response,
and tdEV were not associated with either early tumor or
durable tumor response, but were associated with worse
progression free and overall survival.
The association of CTC with durable response were
more pronounced compared to early tumor response,
mostly due to stable diseases which remained stable for
a long period of time (no early tumor response convert-
ing to durable response), and responders progressing
within 6 months. It appears that even patients who have
an early tumor response or have a stable tumor can con-
tinue to disseminate CTC, but these patients are at a
high risk for early tumor progression. Therefore CTC
could be a reflection of the metastatic potential and
aggressiveness of the tumor as postulated by De Wit
et al. and others, and determines how fast the tumor can
return after an observed tumor response [10, 13, 17].
Another possibility is that CTC may undergo endothelial
to mesenchymal transition (EMT), inducing increased
expression of genes related to resistance to chemother-
apy, which are also seen in possible cancer stem cells
[32–35]. Vesicles also continue to be disseminated from
patients with early tumor responses, possibly due to
apoptosis of tumor cells.Unfortunately, the clinical applicability of CTC in ad-
vanced NSCLC is limited by the low number of CTC
that can be found in 7.5 mL of blood. CTC are only ob-
served in around 30% of patients and their absence
could be due to the low volume of blood screened,
explaining their high specificity but low sensitivity.
Methods to yield higher numbers of CTC are being
developed, for example by exploring larger blood vol-
umes such as is observed with diagnostic leukapheresis
[36–39]. Additionally, when more CTC are available
functional analysis can be performed, which could
further improve predictive values.
Despite the low detection rate, the presence of CTC,
when detected, has clinical implications for survival and
response rates. As it is a marker of decreased response
when detected, the low detection rate is less of a con-
cern. If our results are confirmed in a larger cohort,
CTC could be useful for monitoring disease, allowing
for early cessation of treatment with checkpoint inhibi-
tors, omitting CT scans and preventing patients being
treated with inferior and aggressive treatment at the end
of life.
It is known that CTC are related with survival in
NSCLC and several studies have shown that the pres-
ence of CTC are predictive of worse tumor response to
chemotherapy and targeted therapies [6, 9, 11, 15, 16,
40–46]. CTC in advanced NSCLC are not a homoge-
neous population. PD-L1 expressing tumors can shed
PD-L1+ CTC and these cells are associated with a lower
tumor response to checkpoint inhibitors when measured
at start of therapy and after 3 months [47–49]. In one
study, it was found that patients who had PD-L1 negative
CTC 6 months after the start of checkpoint inhibitors
benefitted from immunotherapy in most cases, while
patients who had PD-L1 positive CTC at that time all pro-
gressed. These studies show that subtyping of CTC is pos-
sible but their meaning without correction for clinical
factors is not known and warrant further analysis.Conclusion
We observed CTC in one third of advanced NSCLC pa-
tients, who on the long term respond worse towards
checkpoint inhibitors. This provides an additional tool for
the prediction of checkpoint inhibitor responsiveness,
which may be of particular interest for patients in whom
no tumor tissue is available for other predictive analysis.Funding
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